EBioMedicine (Jul 2016)
ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease
- Florent Letronne,
- Geoffroy Laumet,
- Anne-Marie Ayral,
- Julien Chapuis,
- Florie Demiautte,
- Mathias Laga,
- Michel E. Vandenberghe,
- Nicolas Malmanche,
- Florence Leroux,
- Fanny Eysert,
- Yoann Sottejeau,
- Linda Chami,
- Amandine Flaig,
- Charlotte Bauer,
- Pierre Dourlen,
- Marie Lesaffre,
- Charlotte Delay,
- Ludovic Huot,
- Julie Dumont,
- Elisabeth Werkmeister,
- Franck Lafont,
- Tiago Mendes,
- Franck Hansmannel,
- Bart Dermaut,
- Benoit Deprez,
- Anne-Sophie Hérard,
- Marc Dhenain,
- Nicolas Souedet,
- Florence Pasquier,
- David Tulasne,
- Claudine Berr,
- Jean-Jacques Hauw,
- Yves Lemoine,
- Philippe Amouyel,
- David Mann,
- Rebecca Déprez,
- Frédéric Checler,
- David Hot,
- Thierry Delzescaux,
- Kris Gevaert,
- Jean-Charles Lambert
Affiliations
- Florent Letronne
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Geoffroy Laumet
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Anne-Marie Ayral
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Julien Chapuis
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Florie Demiautte
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Mathias Laga
- Department of Medical Protein Research, VIB, Ghent, Belgium
- Michel E. Vandenberghe
- CEA, DSV, I2BM, MIRCen, Fontenay aux Roses, France
- Nicolas Malmanche
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Florence Leroux
- Institut Pasteur de Lille, F59000 Lille, France
- Fanny Eysert
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Yoann Sottejeau
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Linda Chami
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS, Laboratoire d'Excellence Distalz, Nice, France
- Amandine Flaig
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Charlotte Bauer
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS, Laboratoire d'Excellence Distalz, Nice, France
- Pierre Dourlen
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Marie Lesaffre
- Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 – M3T – Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France
- Charlotte Delay
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Ludovic Huot
- Institut Pasteur de Lille, F59000 Lille, France
- Julie Dumont
- Institut Pasteur de Lille, F59000 Lille, France
- Elisabeth Werkmeister
- Institut Pasteur de Lille, F59000 Lille, France
- Franck Lafont
- Institut Pasteur de Lille, F59000 Lille, France
- Tiago Mendes
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Franck Hansmannel
- INSERM, U954, Vandoeuvre-lès-Nancy, France
- Bart Dermaut
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- Benoit Deprez
- Institut Pasteur de Lille, F59000 Lille, France
- Anne-Sophie Hérard
- CEA, DSV, I2BM, MIRCen, Fontenay aux Roses, France
- Marc Dhenain
- CEA, DSV, I2BM, MIRCen, Fontenay aux Roses, France
- Nicolas Souedet
- CEA, DSV, I2BM, MIRCen, Fontenay aux Roses, France
- Florence Pasquier
- Univ. Lille, Inserm, U1171, - Degenerative & Vascular Cognitive Disorders, Laboratoire d'Excellence Distalz, F-59000 Lille, France
- David Tulasne
- Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 – M3T – Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France
- Claudine Berr
- INSERM, U1061, Université de Montpellier I, Hôpital La Colombière, Montpellier, France
- Jean-Jacques Hauw
- APHP-Raymond Escourolle Neuropathology Laboratory, la salpétrière Hospital, Paris, France
- Yves Lemoine
- Institut Pasteur de Lille, F59000 Lille, France
- Philippe Amouyel
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- David Mann
- Institute of Brain, Behaviour and Mental Health, University of Manchester, Salford Royal Hospital, Salford, UK
- Rebecca Déprez
- Institut Pasteur de Lille, F59000 Lille, France
- Frédéric Checler
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS, Laboratoire d'Excellence Distalz, Nice, France
- David Hot
- Institut Pasteur de Lille, F59000 Lille, France
- Thierry Delzescaux
- CEA, DSV, I2BM, MIRCen, Fontenay aux Roses, France
- Kris Gevaert
- Department of Medical Protein Research, VIB, Ghent, Belgium
- Jean-Charles Lambert
- INSERM, U1167, Laboratoire d'Excellence Distalz, F59000 Lille, France
- DOI
- https://doi.org/10.1016/j.ebiom.2016.06.002
- Journal volume & issue
-
Vol. 9,
no. C
pp. 278 – 292
Abstract
Although several ADAMs (A disintegrin-like and metalloproteases) have been shown to contribute to the amyloid precursor protein (APP) metabolism, the full spectrum of metalloproteases involved in this metabolism remains to be established. Transcriptomic analyses centred on metalloprotease genes unraveled a 50% decrease in ADAM30 expression that inversely correlates with amyloid load in Alzheimer's disease brains. Accordingly, in vitro down- or up-regulation of ADAM30 expression triggered an increase/decrease in Aβ peptides levels whereas expression of a biologically inactive ADAM30 (ADAM30mut) did not affect Aβ secretion. Proteomics/cell-based experiments showed that ADAM30-dependent regulation of APP metabolism required both cathepsin D (CTSD) activation and APP sorting to lysosomes. Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered Aβ42 secretion in neuron primary cultures, soluble Aβ42 and amyloid plaque load levels in the brain and concomitantly enhanced CTSD activity and finally rescued long term potentiation alterations. Our data thus indicate that lowering ADAM30 expression may favor Aβ production, thereby contributing to Alzheimer's disease development.
Keywords